Dietary Supplement Listing Act of 2026
Sponsored By: Senator Durbin, Richard J. [D-IL]
Introduced
Summary
Mandatory FDA listing of all dietary supplements would require manufacturers to submit product labels, ingredients, claims, and contact details to the Food and Drug Administration and make most of that information searchable. The bill also creates product listing numbers and lets the FDA treat failures to list as misbranding.
Show full summary
- Consumers and families get a publicly searchable database of supplement labels, ingredients, and on-label claims. The database must be established within 2 years.
- Manufacturers, packers, and distributors would have to submit detailed listings that include labels, ingredient amounts, form, warnings, and contact info. Products marketed by January 1, 2027 must be listed within 18 months after enactment and listings must be updated within 30 days of changes.
- Regulators gain new enforcement tools. The FDA could treat failure to file or update a listing as misbranding, prohibit products tied to debarred persons from interstate commerce, and require facility and ingredient source addresses within 10 days of request.
*Would authorize about $7.9 million for FY2026 and $6.6 million annually for FY2027–2030 to set up and run the listing system and public database.*
Your PRIA Score
Personalized for You
How does this bill affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this bill and every other piece of legislation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
3 provisions identified: 2 benefits, 0 costs, 1 mixed.
Mandatory supplement listings and database
This bill would require every dietary supplement sold in the U.S. to be listed with the FDA by the responsible person or the U.S. agent. Listings would include product identity, full label text, full ingredient lists and amounts per serving, directions, warnings, claims, and contact info, with certain proprietary blend amounts and some contact fields withheld from public view. Products on the market by January 1, 2027 would need to be listed within 18 months after enactment; new products after that date would be listed when first introduced. The FDA would assign a unique listing number (which can cover identical formulations) and must create a public, searchable database within two years; failures to file or update listings could be treated as misbranding and subject to enforcement, and companies must update listings within 30 days of label changes and provide facility and ingredient-source addresses to FDA on request within 10 days.
Ban on supplements from debarred persons
This bill would make it unlawful to introduce into interstate commerce any dietary supplement that was prepared, packed, or held with the assistance of, or at the direction of, a person debarred under federal section 306. The rule would block interstate sale of supplements tied to debarred supply-chain actors to protect consumers and supply-chain integrity.
Funding to run supplement listing program
This bill would authorize funding to carry out the supplement listing program and hire staff. It would authorize $7,872,984 for fiscal year 2026 and $6,615,000 for each year from 2027 through 2030. These are authorization amounts; Congress would still need to appropriate the money before the FDA could spend it.
Sponsors & CoSponsors
Sponsor
Durbin, Richard J. [D-IL]
IL • D
Cosponsors
There are no cosponsors for this bill.
Roll Call Votes
No roll call votes available for this bill.
View on Congress.gov